JP2022524997A5 - - Google Patents
Info
- Publication number
- JP2022524997A5 JP2022524997A5 JP2021552624A JP2021552624A JP2022524997A5 JP 2022524997 A5 JP2022524997 A5 JP 2022524997A5 JP 2021552624 A JP2021552624 A JP 2021552624A JP 2021552624 A JP2021552624 A JP 2021552624A JP 2022524997 A5 JP2022524997 A5 JP 2022524997A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- jak1
- pathway inhibitor
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025026650A JP2025087734A (ja) | 2019-03-05 | 2025-02-21 | 慢性肺同種移植片機能不全の治療のためのｊａｋ１経路阻害剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962814085P | 2019-03-05 | 2019-03-05 | |
| US62/814,085 | 2019-03-05 | ||
| PCT/US2020/021088 WO2020181034A1 (en) | 2019-03-05 | 2020-03-05 | Jak1 pathway inhibitors for the treatment of chronic lung allograft dysfunction |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025026650A Division JP2025087734A (ja) | 2019-03-05 | 2025-02-21 | 慢性肺同種移植片機能不全の治療のためのｊａｋ１経路阻害剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022524997A JP2022524997A (ja) | 2022-05-11 |
| JP2022524997A5 true JP2022524997A5 (enExample) | 2023-03-13 |
Family
ID=69941525
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021552624A Pending JP2022524997A (ja) | 2019-03-05 | 2020-03-05 | 慢性肺同種移植片機能不全の治療のためのｊａｋ１経路阻害剤 |
| JP2025026650A Pending JP2025087734A (ja) | 2019-03-05 | 2025-02-21 | 慢性肺同種移植片機能不全の治療のためのｊａｋ１経路阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025026650A Pending JP2025087734A (ja) | 2019-03-05 | 2025-02-21 | 慢性肺同種移植片機能不全の治療のためのｊａｋ１経路阻害剤 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11406640B2 (enExample) |
| EP (2) | EP4691567A3 (enExample) |
| JP (2) | JP2022524997A (enExample) |
| KR (1) | KR20210137087A (enExample) |
| CN (1) | CN114007621A (enExample) |
| AU (1) | AU2020232757B2 (enExample) |
| CA (1) | CA3132371A1 (enExample) |
| EA (1) | EA202192426A1 (enExample) |
| IL (1) | IL285999B2 (enExample) |
| MA (1) | MA55201A (enExample) |
| MX (2) | MX2021010545A (enExample) |
| PH (1) | PH12021552130A1 (enExample) |
| SG (1) | SG11202109563WA (enExample) |
| UA (1) | UA130579C2 (enExample) |
| WO (1) | WO2020181034A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021004063A2 (pt) | 2018-09-04 | 2021-05-25 | Theravance Biopharma R&D Ip, Llc | amidas heterocíclicas com 5 a 7 membros como inibidores de jak |
| DK3837258T3 (da) | 2018-09-04 | 2024-07-22 | Theravance Biopharma R&D Ip Llc | Dimethyl amino azetidine amides as jak inhibitors |
| EP3853229A1 (en) | 2018-10-29 | 2021-07-28 | Theravance Biopharma R&D IP, LLC | 2-azabicyclo hexane compound as jak inhibitor |
| KR20210109522A (ko) | 2018-10-31 | 2021-09-06 | 인사이트 코포레이션 | 혈액 질환의 치료를 위한 병용 요법 |
| UA130579C2 (uk) * | 2019-03-05 | 2026-03-25 | Інсайт Корпорейшн | Інгібітори шляхів jak1 для лікування хронічної дисфункції алотрансплантата легень |
| US11992490B2 (en) | 2019-10-16 | 2024-05-28 | Incyte Corporation | Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP) |
| KR20220149585A (ko) | 2020-03-02 | 2022-11-08 | 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 | Jak 억제제 화합물의 결정성 수화물 |
| CN117120055A (zh) * | 2021-01-11 | 2023-11-24 | 因赛特公司 | 包含jak通路抑制剂和rock抑制剂的组合疗法 |
| CA3207859A1 (en) * | 2021-01-11 | 2022-07-14 | Incyte Corporation | Combination therapy comprising jak pathway inhibitor and rock inhibitor |
| TW202317550A (zh) | 2021-06-25 | 2023-05-01 | 美商施萬生物製藥研發 Ip有限責任公司 | 作為jak抑制劑之咪唑吲唑化合物 |
| KR102952944B1 (ko) | 2021-10-15 | 2026-04-14 | 주식회사 엘지에너지솔루션 | 용접봉 체결 방법 및 이에 의해 용접봉이 수직으로 체결된 용접 장치 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1294358B1 (en) | 2000-06-28 | 2004-08-18 | Smithkline Beecham Plc | Wet milling process |
| HUE028588T2 (hu) | 2005-12-13 | 2016-12-28 | Incyte Holdings Corp | Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok |
| EP2001881A2 (en) | 2006-03-07 | 2008-12-17 | Endacea, Inc. | Compositions and methods for treating respiratory disorders |
| US8058227B2 (en) | 2006-10-03 | 2011-11-15 | Medical University Of South Carolina | Method of treating fibrosis in a subject in need thereof comprising administering a composition comprising a CSD |
| EP2740731B1 (en) | 2007-06-13 | 2016-03-23 | Incyte Holdings Corporation | Crystalline salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
| EP2684564A1 (en) | 2008-04-17 | 2014-01-15 | Sanofi | Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or in the prevention of atrial fibrillation |
| NZ596479A (en) | 2009-05-22 | 2014-01-31 | Incyte Corp | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| TW201113285A (en) | 2009-09-01 | 2011-04-16 | Incyte Corp | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| EP4782062A2 (en) | 2009-12-01 | 2026-07-29 | AbbVie Inc. | Novel tricyclic compounds |
| CA2792508C (en) | 2010-03-10 | 2018-01-16 | Incyte Corporation | Piperidin-4-yl azetidine derivatives as jak1 inhibitors |
| RU2013120966A (ru) | 2010-10-08 | 2014-11-20 | Эббви Инк. | ФУРО[3,2-d]ПИРИМИДИНОВЫЕ СОЕДИНЕНИЯ |
| ES2536415T3 (es) | 2010-11-19 | 2015-05-25 | Incyte Corporation | Pirrolopiridinas y pirrolopirimidinas sustituidas heterocíclicas como inhibidores de JAK |
| CA2818542A1 (en) | 2010-11-19 | 2012-05-24 | Incyte Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
| US8691807B2 (en) | 2011-06-20 | 2014-04-08 | Incyte Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors |
| TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物 |
| UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
| TW201406761A (zh) | 2012-05-18 | 2014-02-16 | Incyte Corp | 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物 |
| EP3450434B1 (en) | 2012-06-15 | 2021-02-24 | CoNCERT Pharmaceuticals, Inc. | Deuterated derivatives of ruxolitinib |
| BR112015003153A2 (pt) | 2012-08-17 | 2017-07-04 | Concert Pharmaceuticals Inc | baricitinib deuterado |
| CA2888816A1 (en) | 2012-11-01 | 2014-05-08 | Incyte Corporation | Tricyclic fused thiophene derivatives as jak inhibitors |
| EP3489239B1 (en) | 2013-03-06 | 2021-09-15 | Incyte Holdings Corporation | Processes and intermediates for making a jak inhibitor |
| CR20190156A (es) * | 2013-05-17 | 2019-05-16 | Incyte Corp | Derivados de bipirazol como inhibidores jak |
| MX376856B (es) | 2013-08-07 | 2025-03-07 | Incyte Holdings Corp | Formas de dosificacion de liberacion prolongada para un inhibidor de jak 1 (cinasa de janus 1). |
| EP3060234A1 (en) * | 2013-10-24 | 2016-08-31 | AbbVie Inc. | Jak1 selective inhibitor and uses thereof |
| SG11201607083VA (en) * | 2014-02-28 | 2016-09-29 | Incyte Corp | Jak1 inhibitors for the treatment of myelodysplastic syndromes |
| SG11201609016VA (en) | 2014-04-30 | 2016-11-29 | Incyte Corp | Processes of preparing a jak1 inhibitor and new forms thereto |
| WO2015184305A1 (en) * | 2014-05-30 | 2015-12-03 | Incyte Corporation | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 |
| TWI710560B (zh) | 2015-11-03 | 2020-11-21 | 美商施萬生物製藥研發Ｉｐ有限責任公司 | 用於治療呼吸疾病之jak激酶抑制劑化合物 |
| CN105294699B (zh) * | 2015-12-04 | 2019-06-11 | 上海勋和医药科技有限公司 | 巴瑞替尼的制备方法 |
| EA201990523A1 (ru) * | 2016-10-03 | 2019-10-31 | НОВЫЕ СЕЛЕКТИВНЫЕ ИНГИБИТОРЫ Jak1 И ИХ ПРИМЕНЕНИЕ | |
| EP3327020A1 (en) * | 2016-11-29 | 2018-05-30 | Sandoz Ag | Citrate salts of a janus kinase (jak) inhibitor |
| TWI754019B (zh) | 2017-03-09 | 2022-02-01 | 美商施萬生物製藥研發 Ip有限責任公司 | 含有4員雜環醯胺之jak抑制劑 |
| AU2018261588A1 (en) | 2017-05-01 | 2019-10-31 | Theravance Biopharma R&D Ip, Llc | Methods of treatment using a JAK inhibitor compound |
| AR111495A1 (es) | 2017-05-01 | 2019-07-17 | Theravance Biopharma R&D Ip Llc | Compuestos de imidazo-piperidina fusionada como inhibidores de jak |
| MD3746429T2 (ro) | 2018-01-30 | 2022-08-31 | Incyte Corp | Procedee pentru prepararea de (1-(3-fluoro-2-(trifluorometil)izonicotinil)piperidin-4-onă) |
| CA3091339A1 (en) | 2018-02-16 | 2019-08-22 | Incyte Corporation | Jak1 pathway inhibitors for the treatment of cytokine-related disorders |
| KR20260080448A (ko) | 2018-03-30 | 2026-06-02 | 인사이트 코포레이션 | Jak 억제제를 사용하는 화농성 한선염의 치료 |
| CN112567247A (zh) | 2018-04-13 | 2021-03-26 | 因赛特公司 | 用于移植物抗宿主病的生物标志物 |
| KR20210109522A (ko) | 2018-10-31 | 2021-09-06 | 인사이트 코포레이션 | 혈액 질환의 치료를 위한 병용 요법 |
| US11596632B2 (en) | 2018-12-19 | 2023-03-07 | Incyte Corporation | JAK1 pathway inhibitors for the treatment of gastrointestinal disease |
| UA130579C2 (uk) | 2019-03-05 | 2026-03-25 | Інсайт Корпорейшн | Інгібітори шляхів jak1 для лікування хронічної дисфункції алотрансплантата легень |
| US11624751B2 (en) | 2019-03-19 | 2023-04-11 | Incyte Corporation | Biomarkers for vitiligo |
-
2020
- 2020-03-05 UA UAA202105585A patent/UA130579C2/uk unknown
- 2020-03-05 IL IL285999A patent/IL285999B2/en unknown
- 2020-03-05 JP JP2021552624A patent/JP2022524997A/ja active Pending
- 2020-03-05 SG SG11202109563WA patent/SG11202109563WA/en unknown
- 2020-03-05 WO PCT/US2020/021088 patent/WO2020181034A1/en not_active Ceased
- 2020-03-05 KR KR1020217031644A patent/KR20210137087A/ko active Pending
- 2020-03-05 MA MA055201A patent/MA55201A/fr unknown
- 2020-03-05 AU AU2020232757A patent/AU2020232757B2/en active Active
- 2020-03-05 EA EA202192426A patent/EA202192426A1/ru unknown
- 2020-03-05 CA CA3132371A patent/CA3132371A1/en active Pending
- 2020-03-05 PH PH1/2021/552130A patent/PH12021552130A1/en unknown
- 2020-03-05 MX MX2021010545A patent/MX2021010545A/es unknown
- 2020-03-05 EP EP25213638.7A patent/EP4691567A3/en active Pending
- 2020-03-05 EP EP20713496.6A patent/EP3934651A1/en not_active Withdrawn
- 2020-03-05 CN CN202080024215.0A patent/CN114007621A/zh active Pending
- 2020-03-05 US US16/810,045 patent/US11406640B2/en active Active
-
2021
- 2021-09-02 MX MX2024007081A patent/MX2024007081A/es unknown
-
2022
- 2022-06-30 US US17/854,443 patent/US11896595B2/en active Active
-
2025
- 2025-02-21 JP JP2025026650A patent/JP2025087734A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022514089A5 (enExample) | ||
| JP2023532257A5 (enExample) | ||
| CA2368675C (en) | Agent for prophylaxis and treatment of interstitial pneumonia and pulmonary fibrosis | |
| US8569325B2 (en) | Method of treatment with coadministration of aspirin and prasugrel | |
| KR20080005601A (ko) | Ｐｄｅ４ 억제제 로플루밀라스트와 테트라히드로비오프테린유도체의 조합 | |
| RU2009149687A (ru) | Фармацевтические композиции и способы лечения сухих кератитов | |
| CN100352442C (zh) | 药物组合 | |
| JP2007534730A (ja) | 少なくとも一つのピロロベンゾジアゼピン誘導体とフルダラビンとを含有する治療用組成物 | |
| JP2010529200A5 (enExample) | ||
| JPWO2000057913A1 (ja) | 間質性肺炎・肺線維症の予防・治療薬 | |
| US20140301980A1 (en) | Methods for the treatment of psoriatic arthritis using apremilast | |
| EA015122B1 (ru) | Фармацевтическая композиция и ее применение для лечения тромбоза | |
| US20080108669A1 (en) | Use 541 | |
| CN114007621A (zh) | 用于治疗慢性肺同种异体移植物功能障碍的jak1途径抑制剂 | |
| MXPA02004871A (es) | Combinaciones farmaceuticas. | |
| CN102149377A (zh) | 决奈达隆在制备用于预防中风或短暂性缺血发作的药物中的用途 | |
| ZA200707930B (en) | Roflumilast for the treatment of pulmonary hypertension | |
| WO2024155965A3 (en) | Biomarkers for use in integrin inhibitor therapy | |
| JP2012532866A (ja) | ６−（５−クロロ−２−ピリジル）−５−［（４−メチル−１−ピペラジニル）カルボニルオキシ］−７−オキソ−６，７−ジヒドロ−５ｈ−ピロロ［３，４−ｂ］ピラジンの配合物 | |
| JP2013528649A5 (enExample) | ||
| WO2018217139A4 (ru) | Новые ингибиторы глутаминилциклаз и их применение для лечения различных заболеваний | |
| JP2024503021A5 (enExample) | ||
| FI4333840T3 (fi) | Jak1-reitin estäjiä kyhmykutinan hoitoon | |
| JP2023527358A5 (enExample) | ||
| JP7527662B2 (ja) | ピモジドとメトトレキサートの医薬組成物、及びその使用 |